<article id="key_messages" class="slide" data-ag-slide-name="Key Messages">
  <div class="basic">
    <div id="summary_main_bg" class="main_content_style">
      <h1 data-ag-editable="Key Messages Main Title">With Neulasta<sup>速</sup> you can give your patients:</h1>
      <ul data-ag-editable="Key Messages Main List">
        <li>
          Neulasta<sup>速</sup> gives better protection from neutropenic events than current practice daily G-CSF<sup>1,2</sup>
        </li>
        <li>
          Neulasta<sup>速</sup> can help optimise chemotherapy delivery<sup>3</sup>
        </li>
        <li>
          Neulasta<sup>速</sup> primary prophylaxis for patients at high risk of FN is a cost-effective solution<sup>4</sup>    
        </li>
      </ul>
      <div id="vaccine_img" data-ag-editable="Key Messages Vaccine HTML">
        <img data-ag-editable="Key Messages Vaccine Image" src="content/images/carer_pages/summary_page_bg.png"/>
      </div>
    </div>
  </div>
  <div class="lightbox_data" id="key_messages_refs">
    <div class="main_content_style">
      <p>
        <strong data-ag-editable="Key Messages References Title">References:</strong>
      </p>
      <div data-ag-editable="Key Messages References List">
        <ol>
          <li>von Minckwitz G, <em>et al.</em> Eur J Cancer 2009;45:608-617.</li>
          <li>Aapro M, <em>et al.</em> Crit Rev Oncol Hematol 2010;74(3):203-10.</li>
          <li>Leonard R, <em>et al.</em> Eur J Cancer Suppl 2009:7(2):270#PD5033.</li>
          <li>Borget I, <em>et al.</em> EJHP Practice 2009;15,58-61.</li>    
        </ol>
      </div>
    </div>
  </div>
</article>